OS favored nivolumab plus chemotherapy or nivolumab plus ipilimumab versus chemotherapy across most prespecified subgroups in patients with tumor cell PD‐L1 expression ≥1% (Figure S1) and in the overall population (Figure S2) including age, sex, race, ECOG performance status, and disease stage at baseline. The gene discussed is CD274; the disease is neoplasm.